share_log

開拓藥業-B:截至二零二四年三月三十一日止月份之股份發行人的證券變動月報表

KINTOR PHARMA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

香港交易所 ·  Apr 5 04:32
Summary by Moomoo AI
開拓藥業-B(09939.HK)於2024年4月5日向香港交易及結算所有限公司提交了最新的證券變動月報表,報告截至2024年3月31日的公司股份變動情況。報告顯示,公司的法定/註冊股本在過去一個月內未發生變動,上月底結存及本月底結存均為700,000,000股,每股面值0.0001美元,法定/註冊股本總額維持在70,000美元。此外,報告中確認了公司在本月發行的證券已獲得董事會的正式授權,並且已履行了所有上市前的法定要求。開拓藥業-B為一家在開曼群島註冊成立的有限公司,由主席、執行董事及行政總裁童友之呈交本次報告。
開拓藥業-B(09939.HK)於2024年4月5日向香港交易及結算所有限公司提交了最新的證券變動月報表,報告截至2024年3月31日的公司股份變動情況。報告顯示,公司的法定/註冊股本在過去一個月內未發生變動,上月底結存及本月底結存均為700,000,000股,每股面值0.0001美元,法定/註冊股本總額維持在70,000美元。此外,報告中確認了公司在本月發行的證券已獲得董事會的正式授權,並且已履行了所有上市前的法定要求。開拓藥業-B為一家在開曼群島註冊成立的有限公司,由主席、執行董事及行政總裁童友之呈交本次報告。
PIONEERING PHARMACEUTICAL-B (09939.HK) FILED ITS LATEST SECURITIES CHANGE MONTH REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON APRIL 5, 2024, REPORTING THE CHANGES IN COMPANY SHARES FOR THE YEAR ENDED MARCH 31, 2024. The report shows that the company's regulated/registered share capital has not changed in the past month, with 700,000,000 shares outstanding at the end of last month and deposits at the end of this month, with a face value of $0.0001 per share, and the total regulated/registered share capital remained at $70,000. In addition, the report confirms that the securities issued by the company this month have been formally authorized by the Board of Directors and have met all pre-listing regulatory requirements. Discovery Pharmaceuticals-B is a limited company incorporated in the Cayman Islands and presented this report by the Chairman, Executive Director and Chief Executive Officer, Tofu Yui.
PIONEERING PHARMACEUTICAL-B (09939.HK) FILED ITS LATEST SECURITIES CHANGE MONTH REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON APRIL 5, 2024, REPORTING THE CHANGES IN COMPANY SHARES FOR THE YEAR ENDED MARCH 31, 2024. The report shows that the company's regulated/registered share capital has not changed in the past month, with 700,000,000 shares outstanding at the end of last month and deposits at the end of this month, with a face value of $0.0001 per share, and the total regulated/registered share capital remained at $70,000. In addition, the report confirms that the securities issued by the company this month have been formally authorized by the Board of Directors and have met all pre-listing regulatory requirements. Discovery Pharmaceuticals-B is a limited company incorporated in the Cayman Islands and presented this report by the Chairman, Executive Director and Chief Executive Officer, Tofu Yui.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more